NCT06236451View on ClinicalTrials.gov

Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia

PHASE4RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 5, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

November 30, 2025

Conditions
Schizophrenia
Interventions
DRUG

Aripiprazole

Aripiprazole will be started at dose of 10 mg/day and increased to a stable dose of 20 mg/day over 2-3 weeks and will be continued till 12 weeks.

DRUG

Risperidone

Risperidone will be started at dose of 2 mg/day and increased to a stable dose of 6 mg/day over 2-3 weeks and continued till 12 weeks.

Trial Locations (1)

751019

RECRUITING

All India Institute of Medical Sciences (AIIMS), Bhubaneswar

All Listed Sponsors
lead

All India Institute of Medical Sciences, Bhubaneswar

OTHER